$1.82
-0.07 (-3.70%)
Open$1.88
Previous Close$1.89
Day High$1.95
Day Low$1.80
52W High$2.95
52W Low$0.80
Volume—
Avg Volume522.3K
Market Cap280.00M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+229.7% upside
Current
$1.82
$1.82
Target
$6.00
$6.00
$4.29
$6.00 avg
$7.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 59.3K | 9.23M | 9.01M |
| Net Income | -100,473,941 | -678,125 | -522,642 |
| Profit Margin | -155,587.4% | -7.4% | -5.8% |
| EBITDA | -105,348,008 | -963,511 | -904,753 |
| Free Cash Flow | — | -508,030 | -465,093 |
| Rev Growth | — | +6.0% | +24.9% |
| Debt/Equity | 0.02 | 0.23 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |